Legal & General Group
IRD

Legal & General Group’s Opus Genetics IRD Stock Holding History

Legal & General Group’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.4K Buy
+5,203
New +$24.3K ﹤0.01% 3087

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Legal & General Group's IRD Position: Q2 2026 in Review

Legal & General Group opened a new position in Opus Genetics (IRD) in Q2 2026: 5,203 shares worth $21.4K. The stake represents ﹤0.01% of the portfolio and ranks #3087 among its holdings.

103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Legal & General Group held 5,203 shares of Opus Genetics worth $21.4K as of Q2 2026.
  • Opus Genetics was a new Legal & General Group position in Q2 2026.
  • Opus Genetics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3087 holding.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.